Day: November 12, 2020

WOODCLIFF LAKE, NJ, Nov. 12, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third quarter of 2020, ended September 30, 2020. John Koconis, Chief Executive Officer of Timber, commented, “During the third quarter the management team of Timber has been working hard on all fronts of the Company’s operations. This includes advancing our two ongoing Phase 2b clinical trials for orphan indications, exploring strategic options for the two assets acquired from BioPharmX Corp, and investigating options to improve the capital structure of the Company....

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — First Majestic Silver Corp. (“First Majestic” or the “Company”) announced today that its Mexican subsidiary Primero Empresa Minera, S.A. de C.V. (“PEM”) has now been provided with written reasons for the decision made on September 23, 2020 by the Mexican Federal Court on Administrative Matters (“Federal Court”), nullifying the Advance Pricing Agreement (“APA”) concluded in 2012 between PEM and the Mexican tax authority, Servicio de Administracion Tributaria (“SAT”).The Federal Court’s decision directs SAT to re-examine the evidence and basis for the issuance of the APA with retroactive effect, for the following key reasons (i) SAT’s errors in analyzing PEM’s request for the APA and the evidence provided in support of the request; and (ii) SAT’s...

AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it is commencing an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. The Company expects to grant the underwriters a 30‐day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.Cantor Fitzgerald & Co. is acting as sole book-running manager for the proposed offering.Cassava Sciences intends to use the net proceeds, if any, from the sale of the shares of common stock...

SALISBURY, Md., Nov. 12, 2020 (GLOBE NEWSWIRE) — Partners Bancorp (NASDAQ: PTRS) (the “Company”), the parent company of The Bank of Delmarva (“Delmarva”), Seaford, Delaware, and Virginia Partners Bank (“Virginia Partners”), Fredericksburg, Virginia, announced today that its Board of Directors has approved a stock purchase plan. Under the plan, the Company is authorized to purchase up to 356,000 outstanding shares of its common stock. The Company may repurchase shares in the open market or through privately negotiated transactions.Lloyd B. Harrison, III, the Company’s Chief Executive Officer, commented, “We consider this to be in the best interests of the Company as it may be expected to improve the Company’s operating performance on a per share basis and enhance, in the long term, the market price per share of the Company’s common...

CHIHUAHUA, Mexico, Nov. 12, 2020 (GLOBE NEWSWIRE) — Grupo Cementos de Chihuahua, S.A.B. de C.V. (BMV: GCC*, or “the Company”), a leading producer of cement and concrete in the United States and Mexico, announced today that it has obtained a favorable resolution in the annulment of the “Damages Award”, in the arbitration process commenced by Compañía de Inversiones Mercantiles, S.A. (“CIMSA”), against the Company and pursuant to the Inter-American Commission on International Commercial Arbitration.This annulment was notified by the highest constitutional justice authority in Bolivia on October 29th of this year. Consequently, all legal proceedings filed in the country of Bolivia have been resolved in favor of GCC.Based on this resolution, the Company will commence the corresponding legal proceedings in the United States to reverse...

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum.Management is scheduled to present Thursday, November 19, 2020 at 2:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.About T2 BiosystemsT2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel,...

Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over TimeThe U.S. 21st Century Cures Act Provides Direction on New Statistical Analyses Using SimulationsTonix Plans to Study TNX-102 SL in a New Phase 3 PTSD Trial in KenyaCHATHAM, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, outlined a new statistical method to analyze future Posttraumatic Stress Disorder (PTSD) drug studies and presented a retrospective analysis using the new method of the Phase 3 HONOR study (P301) of TNX-102 SL (cyclobenzaprine HCl sublingual tablets), for the treatment...